Program now available!
The APLAR 2025 official program is scheduled in the Japanese time zone (UTC+9). To check the program times in your location, use a time zone converter.
As more information becomes available – this page will be updated so please make sure to check back regularly.
Congress Travel Grants
APLAR will award 50 need-based travel stipends to AYR members, covering part of their travel and lodging expenses along with complimentary conference registration.
Workshops information coming soon.
| Workshop | |
|---|---|
|
0730-0800 |
REGISTRATION |
|
0800-1030 |
|
|
1030-1045 |
BREAK |
|
1045-1230 |
|
|
1230-1330 |
BREAK |
|
1330-1500 |
|
|
1500-1515 |
BREAK |
|
1515-1900 |
|
| Concurrent | Concurrent | Concurrent | Concurrent | Concurrent | Concurrent | |
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
BREAK |
||||||
|
|
|
|
How to implement recent guidelines into clinical practice of CTD/SARD-ILDs 1045-1245 hours View information here |
|
|
|
|
Sponsored by
|
||||||
|
LUNCH BREAK |
||||||
|
|
|
|
|
|
|
|
|
Sponsored by
|
Sponsored by
|
|||||
|
1700-1800
|
Opening Ceremony Included in registration. View more information here |
|||||
|
1800-1930
|
Welcome Reception and Official Opening of Exhibition Hall Included in registration. View more information here |
|||||
| Plenary / Concurrent 1 | Concurrent 2 | Concurrent 3 | Concurrent 4 | Concurrent 5 | Concurrent 6 | |
|---|---|---|---|---|---|---|
|
0830-0915 |
|
Breakfast symposium 1
Rheumatoid arthritis in the elderly: Characteristics and treatment considerations View Industry Partner Program |
|
Breakfast symposium 3
Future Directions in MAS and Still’s Disease: Challenges and Opportunities View Industry Partner Program |
|
|
|
|
|
|
||||
|
0920-1050 |
Plenary session 1: State of the art rheumatoid arthritis
Managing rheumatoid arthritis in 2025: Update of EULAR recommendations and further trial insights Josef Smolen The changing landscape of rheumatoid arthritis: Pathogenesis and therapy Ellen Gravallese Updates on DMARDs treatment: global standards and regional adaptations Tsutomu Takeuchi (竹内勤) |
|||||
|
1050-1110 |
Break and poster viewing |
|||||
|
1110-1215 |
|
Morning symposium 2
From SLE to LN – preventing organ damage and progression : an Asian perspective View Industry Partner Program |
|
|
|
|
|
|
|
|
|
|
||
|
1220-1335 |
Future perspectives of rheumatoid arthritis
|
Epidemiology Coordinated by the APLAR Epidemiology SIG |
Abstract session 1 |
State-of-the-Art SLE |
Musculoskeletal Ultrasound Revolution in rheumatology Coordinated by APLAR Young Rheumatologists |
Recent Topics of Sjögren’s Disease (SjD): Pathogenesis, Clinical Practice Guidelines (CPGs) and Clinical trials Coordinated by the APLAR Sjogren SIG |
|
Chairpersons: Yuko Kaneko and Kunihiro Yamaoka
At risk or very early RA Peter Taylor D2T-RA, discontinuation of treatments Gerd Burmester Q&A |
Chairpersons: Md. Nazrul Islam and Srikantiah Chandrashekara
Epidemiology in Rheumatology: Pushing it Forward Evelyn Salido Beyond the Clinic: Public Health Strategies for comprehensive Rheumatic Disease management Nizam Uddin Comparative Epidemiology of Inflammatory Back Pain and Axial Spondyloarthritis: Insights from Asia Pacific to North America Muhammad Ahmed Saeed |
Session agenda will be made available in due course |
Chairpersons: Tsuneyo Mimori and Kenji Oku
Presentation title TBA Speaker TBA New treatment assessments Eric Morand Precision medicine in Systemic lupus erythematosus Shingo Nakayamada Q&A |
Chairpersons: Ghita Harifi and Babur Salim
MSK Ultrasound training : From conventional to innovative methods Myma Albayda Integrating Point-OF-Care Ultrasound in rheumatology practice Bhaskar Dasgupta MSK Ultrasound in the Age of AI: Are We There Yet? Peter Siu Q&A |
Chairpersons: Sandhya Pulukool and Atsushi Kawakami
Presentation title TBA Speaker TBA Pathogenesis and Recent CPGs for SjD Atsushi Kawakami Understanding of Genetics of Sjögren’s disease Maureen Rischmueller Recent Clinical Trials of SjD Hiroto Tsuboi Clinical and Demographic Characteristics of SjD in Asian Populations Sandhya Pulukool |
|
|
1340-1510 |
|
|
|
|
|
|
|
|
||||||
|
1515-1630 |
Autoimmunity and Precision Medicine
|
GRAPPA session
|
Abstract session 2
|
Abstract session 3
|
State-of-the-Art Rheumatology from the Young Generation: AYR, EMEUNET, and J-STAR Collaborative Symposium
|
Current Trends in Gout Management Coordinated by the APLAR Crystal-induced arthritis SIG |
|
Chairpersons: Atsushi Kawakami and Yutaka Kawahito
Precision medicine in SLE Nan Shen Single-cell omics based classification of autoimmune rheumatic diseases Masayuki Nishide Immunophenotyping of autoimmune rheumatic diseases Satoshi Kubo Q&A |
Chairpersons: Katy Leung and Mitsumasa Kishimoto
New developments in PsA Arthur Kavanaugh To lump or split – that is the question Peter Nash Lessons from AXIS Ashish Mathew Discussion |
Session agenda will be made available in due course |
Session agenda will be made available in due course |
Chairpersons: Motomu Hashimoto
|
Chairpersons: Jose Paulo Lorenzo
SGLT2 inhibitors mechanism and treatment in gout Lisa Stamp Clinical Aspects and Management of Gout Sami Salman Altekreeti A multi-disciplinary approach including patient education – the key to success in gout management Binit Vaidya Updates from the APLAR gout registry Kanon Jatuworapruk Q&A |
|
|
1630-1655 |
Break and poster viewing |
|||||
|
1655-1810 |
New treatment strategies for SLE
|
APLAR – ACR symposium: Coordinated by the ACR – International session |
Genomics in Rheumatology, Unraveling the Genetic Code of Autoimmune Diseases Coordinated by the APLAR Genetics SIG |
Women’s Health & Reproductive Issues in RMDs Coordinated by the APLAR Women’s Health & Reproductive Issues in RMDs SIG |
Abstract session 4 |
Hot topics in axSpA Coordinated by the APLAR SpA SIG |
|
Chairpersons: Shinsuke Yasuda and TBA
New treatments Laurent Arnaud Presentation title TBA Speaker TBA How to manage complications Andrea Doria Q&A |
Chairpersons: Tsutomu Takeuchi and Shin-Seok Lee
Update on Epigenetics of Rheumatic Diseases Amr Sawalha Aspects of Targeted Therapies Jonathan Kay |
Chairpersons: Michael Tee and Suleman Khan
Immunogenetic Analysis of Systemic Lupus Erythematosus in Kazakhstani Population Lina Zaripova Genetics in Connective Tissue Diseases Oliver Distler Gene Therapies- How Far We Have Gone Suleman Khan Identification of most Determental Variants and Potential Therapeutic Targets within IL-2 and IL-3 Genes- An In-Silico Approach Fazal Jalil Q&A |
Chairpersons: Vinod Ravindran and Samar Al Emadi
Inflammatory & non-inflammatory low back pain in Pregnancy Saira Elaine Anwer Khan APLAR Consensus statements for reproductive health in women with AIRDs Vinod Ravindran Recurrent Pregnancy Loss in SLE: Predictors and Prevention Claire Barrett Survey of rheumatologists’ awareness and knowledge regarding reproductive rheumatology issues Chen-I Hsieh Q&A |
Session agenda will be made available in due course |
Chairpersons: Fariz Yahya and Muhammad Haroon
Sex and Gender Considerations in AxSpA Muhammad Ahmed Saeed Radiographic progression in axSpA- update on the current status Xenofon Baraliakos Comorbidities in axSpA- the Asia Pacific perspective Lai-Shan Tam |
|
|
1815-1915 |
|
|
Evening symposium 3
Pathophysiology and treatment strategies in systemic lupus erythematosus / Lupus Nephritis View Industry Partner Program |
|
|
Evening symposium 6
Treatment Strategy for Osteoporosis with Rheumatoid Arthritis View Industry Partner Program |
|
|
|
|
||||
|
1930-late |
AYR Networking Reception (members and invitation only) |
|||||
| Plenary / Concurrent 1 | Concurrent 2 | Concurrent 3 | Concurrent 4 | Concurrent 5 | Concurrent 6 | |
|---|---|---|---|---|---|---|
|
0830-0915 |
|
Breakfast symposium
Improving conventional therapy for patients with rheumatoid arthritis by subcutaneous MTX View Industry Partner Program |
Breakfast symposium 7
The importance of IL-6 focusing on Rheumatoid Arthritis and Various Autoimmune-related diseases View Industry Partner Program |
|
|
|
|
|
|
|
|
|||
|
0920-1050 |
Plenary session 2: State of the art systemic lupus erythematosus
Better Medicine for Lupus is here. When will we find it? Joan Merrill Treat to target in SLE: current evidence and future directions Eric Morand State of the art on the use of biological therapies in SLE Marta Mosca |
|||||
|
1050-1110 |
Break and poster viewing |
|||||
|
1110-1215 |
|
|
|
Morning symposium 10
The role of CANAKINUMAB in the Still’s disease treatment paradigm View Industry Partner Program |
Morning symposium 11
The mission for remission: what is now possible for our patients? View Industry Partner Program |
Morning symposium 12
The role and clinical significance of IL-17A and IL-17F in the pathogenesis of SpA View Industry Partner Program |
|
|
|
|
|
|
||
|
1220-1335 |
Childhood-onset SLE
|
Osteoporosis Coordinated by the APLAR Osteoporosis SIG |
Digital Health and Telemedicine Coordinated by the APLAR Digital Health and Telemedicine SIG |
COPCORD Coordinated by the APLAR COPCORD SIG |
Abstract session 5 |
Rheumatoid arthritis Coordinated by the APLAR Rheumatoid arthritis SIG |
|
Chairpersons: Masaaki Mori and Sulaiman Al-Mayouf
Pediatric SLE Guidelines in Japan Masaaki Mori Presentation title TBA Speaker TBA Monogenic Lupus: Lessons from an International Cohort Sulaiman Al-Mayouf CAR-T therapy on Childhood-onset refractory SLE Meiping Lu Q&A |
Chairpersons: Julie Li-Yu, MD and Sumapa Chaiamnuay
Osteoporosis sequencing therapy from UaE perspective Mustafa Al Izzi TBS and clinical applications (comparing 2 guidelines) Sumapa Chaiamnuay Fracture liaison service in Qatar, benefits and challenges Nabeel Abdulla Q&A |
Session agenda will be made available in due course |
Chairpersons: Ashish Mathew and William Taylor
Impact of type 2 diabetes mellitus on the prevalence, clinical presentation and outcome of common musculoskeletal diseases at the community level in Bangladesh Sabrina Yesmin Presentation title TBA Speaker TBA Rapid urbanisation and temporal trends in MSK disorders in China Lai-Shan Tam Q&A |
Session agenda will be made available in due course |
Chairpersons: Zhan-guo Li and Kunihiro Yamaoka
Presentation title TBA Speaker TBA Presentation title TBA Speaker TBA The Rheumatoid Arthritis Patient Registry: Implications for Clinical Practice, Research and the Health System Togizbaev Galymzhan Asylbekovich Q&A |
|
|
1340-1510 |
|
|
Lunch symposium 7
The current screening, monitoring, and treatment for RA-ILD View Industry Partner Program |
|
|
|
|
|
|
|||||
|
1515-1630 |
State-of-the-Art rheumatoid arthritis
|
IJRD session Coordinatred by the International Journal of Rheumatic Diseases |
Navigating the complexities of systemic sclerosis Coordinated by the APLAR Scleroderma SIG |
Deep Dive into IIM: Practical Aspects Coordinated by the APLAR Myositis (IIM) SIG |
Abstract session 6
|
Therapeutic advances in SLE Coordinated by the APLAR SLE SIG |
|
Chairpersons: Isao Matsumoto and Shintaro Hirata
The Role of Age-Associated ThA Cells in Autoimmune Diseases Tomohisa Okamura Presentation title TBA Speaker TBA Organ involvement Peter Taylor Q&A |
Chairpersons: James Wei and Shin-Seok Lee
Global burden and trends of rheumatic diseases Chak Sing Lau Role of APLAR in worldwide rheumatology Tsutomu Takeuchi (竹内勤) How to enhance the journal impact of IJRD? James Wei Q&A |
Chairpersons: Andrea Low and ChingChing Foocharoen
Emerging concepts and updates on management of primary heart involvement in systemic sclerosis Laura Ross Updates on the management and treatment of pulmonary hypertension in systemic sclerosis Hidekata Yasuoka Cell therapy in systemic sclerosis: Lessons learnt from oncology to autoimmunity Francesca Lim |
Chairpersons: Vidya Limaye and Choon Guan Chua
Presentation title TBA Speaker TBA Subclassification/Endotyping of IIM Guochun Wang Management Recommendations of IIM Takahisa Gono Q&A |
Session agenda will be made available in due course |
Chairpersons: Laniyati Hamijoyo and Alberta Hoi
Biological therapies for systemic lupus erythematosus and lupus nephritis Yoshiya Tanaka CAR-T and cellular therapies for SLE Thomas Sau Yan Chan Targeted small molecules and newer immunosuppressive drugs for SLE Chi Chiu Mok |
|
|
1630-1655 |
Break and poster viewing |
|||||
|
1655-1810 |
Surgery of rheumatoid foot and ankle
|
APLAR – EULAR symposium Coordinated by EULAR – International session |
Paediatric Coordinated by the APLAR Paediatric SIG |
Social Commitment & Patient Outreach Coordinated by the APLAR Social Commitment & Patient Outreach SIG |
Pathophysiology of Arthritis and Osteoimmunology |
Cutting edge in vasculitis Coordinated by the APLAR Vasculitis SIG |
|
Chairpersons: Yasuharu Nakashima and Yuichi Mochida
Joint-preserving surgery for rheumatoid forefoot deformity Koichiro Yano Presentation title TBA Lew Schon Q&A |
Chairpersons: Laniyati Hamijoyo and Yoshiya Tanaka
AI in to make imaging more efficient for patients with RA Daniel Aletaha PsA Imaging: what is new? Annamaria Iagnocco Difficult-To-Treat axial Spondyloarthritis: a real problem or just semantics? Xenofon Baraliakos |
Chairpersons: Priscilla Campbell-Stokes and Elizabeth Ang
Paediatric Rheumatology Challenges in Asia Pacific Sumaira Farman APLAR JIA guidelines Thaschawee Arkachaisri Redefining Treatment: Multitarget Approaches for Difficult-to-Treat Pediatric Lupus Nephritis Christine Bernal Takayasu/Vasculitis: Lessons Learnt Sathish Kumar Q&A |
Chairpersons: Nighat Ahmad and TBC
Introduction Nighat Mir Ahmad Delay in diagnosis and initiation of treatment due to shortage of workforce in the Asia-Pacific Syed Atiqul Haq Workforce Productivity and Economic Costs of Rheumatic Diseases Chengappa Kavadichanda Driving safe and effective care through clinical care standards (eg could be around the new Australian care standard for RA) Catherine Hill Q&A |
Chairpersons: Koshiro Sonomoto and TBC
Presentation title TBA Noriko Komatsu Presentation title TBA Masaru Ishii Presentation title TBA Georg Schett Q&A |
Chairpersons: Xinping Tian and Masayoshi Harigai
Clinical insights from immunological phenotypes of microscopic polyangiitis Masayuki Nishide Presentation title TBA Speaker TBA Polymyalgia rheumatica–clinical assessment, imaging, and new treatment Bhaskar Dasgupta Q&A |
|
|
1900-late |
Joint Presidential Gala dinner |
|||||
| Plenary / Concurrent 1 | Concurrent 2 | Concurrent 3 | Concurrent 4 | Concurrent 5 | Concurrent 6 | |
|---|---|---|---|---|---|---|
|
0800-0915 |
Breakthrough Therapies and Emerging Challenges in Systemic Autoimmune Diseases |
Advances in Imaging in Rheumatology Coordinated by the APLAR Imaging SIG |
Surgery of rheumatoid hand |
Management of lung complications in CTDs: Moving forward |
Updates on OA therapy Coordinated by the APLAR Osteoarthritis SIG |
SLE: Comorbidities and less common manifestations Coordinated by the APLAR SLE SIG |
|
Chairpersons: Shingo Nakayamada and Yoshiya Tanaka
Molecular targeted therapies Richard Furie CAR-T and TCE Georg Schett Q&A |
Chairpersons: Kok-Ooi Kong and Ka-Wing Gavin Lee
Presentation title TBA Speaker TBA New sequence and other technological advancement in MRI relevant to the field of rheumatology Gervais Wansaicheong MSK USG – what has been learned in past one year (a year review in literature) Jemima Felicity Albayda |
Chairpersons: Nobunori Takahashi and Toshihisa Kojima
Presentation title TBA Speaker TBA Difficult-to-treat Rheumatoid Arthritis (D2T RA) and Surgical Management of the Hand Hajime Ishikawa Q&A |
Chairpersons: Takao Fujii and Ayako Nakajima
CTD-PAH; how anti-remodeling drugs change treatment landscape Dinesh Khanna CTD-ILD: Personalized treatment based on risk stratification Andrea Low Hsiu Ling PH due to ILD (group 3 PH) Masataka Kuwana Q&A |
Chairpersons: Matthew Jiang and Mohsen Soroush
Barriers to implementation of OA guidelines Inoshi Atukorala OA and semaglutide Shweta Nakarmi IL-23 and CCL17 in OA Kevin Lee Q&A |
Chairpersons: Chi Chiu Mok and Kenji Oku
Assessment and management of osteoporosis and avascular necrosis Sandra Navarra Assessment and management of neuropsychiatric lupus Alberta Hoi Management of thrombotic and obstetric APS in SLE Kenji Oku |
|
|
0920-1050 |
Plenary session 3: State of the art translational research
Human Lupus: An Interferonopathy with Many Twists Virginia Pascual Deep Depletion of B-cells as treatment of autoimmune disease Georg Schett Lymphocytes acquire promigratory and autoimmune phenotypes via the downregulation of lymphocyte-specific protein-1 Wan-Uk Kim |
|||||
|
1050-1110 |
Break and poster viewing |
|||||
|
1110-1225 |
Breakthrough Genetics and Emerging Challenges in Systemic Autoimmune Diseases |
Abstract session 7 |
Systemic JIA |
Interventional rheumatology |
Inborn Erros and Somatic Mosaicsim in Adult Autoinflammatory Diseases |
State-of-the-Art spondyloarthritis |
|
Chairpersons: Kazuhiko Yamamoto and Chikashi Terao
Presentation title TBA Speaker TBA Contribution of gut, endogeneous, and exogenous virome to systemic lupus erythematosus Yukinori Okada Multi-omics Nan Shen Q&A |
Session agenda will be made available in due course
|
Chairpersons: Takako Miyamae and Soamarat Vilaiyuk
Current status and future prospects of clinical practice for systemic juvenile idiopathic arthritis in Japan Masaki Shimizu The CARRA Registry systemic JIA cohort: Clinical patterns, outcomes and treatment in North America Yukiko Kimura Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome Caifeng Li From Diagnosis to Treatment: Applying the EULAR/PReS 2024 Recommendations in Clinical Practice for Still’s Disease — with Considerations for Limited-Resource Settings Soamarat Vilaiyuk Q&A |
Chairpersons: Shigeki Momohara and Yuho Kadono
Presentation title TBA Speaker TBA Presentation title TBA Speaker TBA Cooled Radiofrequency Ablation of Genicular Nerves Seong-Soo Choi Q&A |
Chairpersons: Masaru Kato and Atsushi Kawakami
Presentation title TBA Speaker TBA Single-cell omics based approach in Japanese FMF KI mice Tomohiro Koga Characterization of Japanese VEXAS syndrome from nationwide registry Yohei Kirino Q&A |
Chairpersons: Ippei Miyagawa and Hideto Kameda
Presentation title TBA Speaker TBA Presentation title TBA Speaker TBA Hot topics in AxSpA Peter Nash Q&A |
|
|
1225-1325 |
|
|
|
|
|
|
|
1325-1440 |
Historical Perspectives in Rheumatology
|
Abstract session 8
|
Cutting-edge of Trans-omics Studies on Rheumatic Diseases
|
Pathological skills for rheumatologists
|
Managing safety of JAK inhibitors
|
Pros or cons of glucocorticoid for systemic autoimmune diseases
|
|
Chairpersons: Kazuhiko Yamamoto and Syed Atiqul Haq
Alfred Nobel and his legacy to Rheumatology Kaushik Chaudhuri William Osler and the Rheumatologist of today Rohini Handa Philip Hench and the discovery of Glucocorticoids- Lessons from the past with implications for the future Frank Buttgereit Q&A |
Session agenda will be made available in due course
|
Chairpersons: Haruka Tsuchiya and Sae Ochi
Analysis of Somatic Mutations in Immune Cells in Rheumatic Diseases Keishi Fujio Projecting trans-omics of autoimmune diseases into single cell resolution Yukinori Okada Presentation title TBA Speaker TBA Presentation title TBA Sang-Cheol Bae Q&A |
Chairpersons: Naoto Tamura and Hiroaki Dobashi
Lupus nephritis Keiju Hiromura Presentation title TBA Speaker TBA Q&A |
Chairpersons: Masayoshi Harigai and Akio Morinobu
Post-marketing surveillance Masataka Kuwana Presentation title TBA Speaker TBA Current Perspectives on Malignancy Risk Associated with JAK Inhibitors in Rheumatic Diseases Soo Kyung Cho Q&A |
Chairpersons: Tatsuya Atsumi and Kazuhisa Nakano
Presentation title TBA Speaker TBA Presentation title TBA Speaker TBA Q&A |
|
|
1440-1515 |
Closing ceremony and awards |
|||||
